- Home
- TLSA vs EARN Comparison
TLSA vs EARN Comparison
Compare TLSA & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- EARN
- Stock Information
- Founded
- TLSA 2013
- EARN 2012
- Country
- TLSA United Kingdom
- EARN United States
- Employees
- TLSA N/A
- EARN N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- EARN Real Estate Investment Trusts
- Sector
- TLSA Health Care
- EARN Real Estate
- Exchange
- TLSA Nasdaq
- EARN Nasdaq
- Market Cap
- TLSA 187.0M
- EARN 223.5M
- IPO Year
- TLSA 2000
- EARN 2013
- Fundamental
- Price
- TLSA $1.86
- EARN $5.93
- Analyst Decision
- TLSA
- EARN Buy
- Analyst Count
- TLSA 0
- EARN 2
- Target Price
- TLSA N/A
- EARN $6.13
- AVG Volume (30 Days)
- TLSA 242.1K
- EARN 282.4K
- Earning Date
- TLSA 08-05-2025
- EARN 08-11-2025
- Dividend Yield
- TLSA N/A
- EARN 16.22%
- EPS Growth
- TLSA N/A
- EARN N/A
- EPS
- TLSA N/A
- EARN N/A
- Revenue
- TLSA N/A
- EARN $35,893,000.00
- Revenue This Year
- TLSA N/A
- EARN $3.72
- Revenue Next Year
- TLSA N/A
- EARN $18.60
- P/E Ratio
- TLSA N/A
- EARN N/A
- Revenue Growth
- TLSA N/A
- EARN 43.30
- 52 Week Low
- TLSA $0.63
- EARN $4.33
- 52 Week High
- TLSA $1.91
- EARN $7.14
- Technical
- Relative Strength Index (RSI)
- TLSA 70.48
- EARN 55.19
- Support Level
- TLSA $1.62
- EARN $5.85
- Resistance Level
- TLSA $1.89
- EARN $6.05
- Average True Range (ATR)
- TLSA 0.10
- EARN 0.09
- MACD
- TLSA 0.03
- EARN -0.00
- Stochastic Oscillator
- TLSA 93.48
- EARN 54.55
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.